Form 4: Novavax EVP, CFO and Treasurer James Patrick Kelly Reports Stock Transactions

James Patrick Kelly, EVP, CFO and Treasurer of Novavax Inc, reports the vesting and disposal of shares related to restricted stock units.

Summary

• On March 7, 2025, James Patrick Kelly, the EVP, CFO, and Treasurer of Novavax Inc., reported transactions involving Novavax common stock.
• Kelly exercised restricted stock units (RSUs), converting 12,223 RSUs into common stock.
• Simultaneously, Kelly disposed of 5,904 shares of common stock to cover tax obligations at a price of $8.34 per share.
• Following these transactions, Kelly directly owns 69,251 shares of Novavax common stock and 12,223 derivative securities.
• The RSUs vest in three equal installments on the anniversaries of the March 7, 2023 grant date, contingent upon continued employment.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common for executives holding company stock and equity-based compensation. It provides transparency to investors regarding the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice and are required by the SEC for company insiders.
• The vesting schedule of the RSUs (one-third annually) is a typical vesting arrangement.
• Similar transactions are regularly reported by executives at comparable biotechnology companies such as Moderna (MRNA) and BioNTech (BNTX).

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The disposal of shares to cover tax obligations is a common practice and doesn't necessarily reflect a change in the executive's confidence in the company.

Key Dates